HANDOK Inc.

002390.KS

002390.KSHANDOK Inc. KR flag

KSE

11,720.00

KRW

-60.00

(-0.51%)

161.31BMarket Cap

Jul 31Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7002390003

Return %

Stock

S&P500

-14.14

8.32

-42.12

43.81

-51.06

96.82

Use logarithmic scale

Stock Chart Unavailable

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	26,830.21	27,978.22	28,607	28,894.24	31,793.4	33,567.86	32,989.58	34,450.51	36,575.84	37,548.74	39,495.99	37,956.55	- -	36,833.07
Basic EPS, GAAP	491.86	1,050.2	121	-136	-518	391	590	2,544	1,958	239	776	-2,091	- -	-3,815.94
Free Cash Flow per Basic Share	-572.25	-383.85	1,825.7	-194.74	-3,225.45	-2,727.66	580.68	-1,254.58	121.61	-451.9	-960.21	711.63	- -	-1,610.74
Dividend per Share	247.28	148.45	190.54	150.51	99.91	124.96	243.6	446.32	274.89	299.51	349.9	399.75	- -	- -
Book Value per Share	20,789.22	21,711.04	20,473.49	19,604.33	18,804.1	19,176.76	17,787.12	19,216.92	21,173.69	21,456.97	22,188.17	18,892.17	- -	17,032.65
Tangible Book Value per Share	22,708.35	23,506.36	19,666.91	18,911.86	15,335.72	15,409.75	15,833.98	18,032.18	21,052.37	21,972.16	21,726.42	18,712.2	- -	14,855.6
Basic Weighted Avg Shares	12	12	12	12	12	12	14	14	14	14	14	14	- -	14
Sales/Revenue/Turnover	314,648	327,936	348,311	358,448	396,134	417,970	446,731	473,000	503,612	517,641	543,759	522,741	507,358	507,358
Operating Margin (%)	2.73	2.28	2.96	1.74	0.92	-0.45	4.94	5.81	5.63	5.41	5.24	2.41	0.11	0.11
Depreciation Expense	11,463	11,067	13,075	14,171	14,789	17,655	19,742	21,580	21,454	21,368	21,759	22,488	23,540	23,540
Net Income, GAAP	5,768	12,310	1,473	-1,687	-6,454	4,869	7,990	34,929	26,960	3,295	10,684	-28,797	-52,563	-52,563
Effective Tax Rate (%)	41.82	20.7	59.69	- -	- -	48.43	24.42	30.01	35.96	31.03	- -	- -	- -	- -
Profit Margin (%)	1.83	3.75	0.42	-0.47	-1.63	1.16	1.79	7.38	5.35	0.64	1.96	-5.51	-10.36	-10.36
Working Capital	83,637	78,995	74,129	78,091	49,677	64,535	26,320	41,715	100,525	47,740	83,242	-6,178	-13,442	-13,442
LT Debt	20,048	20,000	54,024	61,494	89,437	105,269	50,271	93,950	154,137	139,475	185,536	124,758	144,148	144,148
Total Equity	287,252	294,276	307,774	303,706	289,250	290,711	313,376	343,995	381,849	383,996	381,856	340,633	289,060	289,060
Return on Invested Capital (%)	1.64	1.73	1.1	- -	- -	-0.2	3.47	3.69	3.04	3.02	- -	- -	- -	- -
Return on Capital (%)	2.3	4.61	0.81	- -	- -	2.18	3.18	9.14	6.2	1.35	- -	- -	- -	- -
Return on Common Equity (%)	2.39	4.94	0.58	-0.69	-2.7	2.06	3.33	13.84	9.71	1.12	3.55	-10.18	-21.25	-21.25

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	3.92%	1.5%	-2.94%
Net Income, GAAP	12.05%	-34.67%	82.53%
Free Cash Flow	2.48%	-194.02%	-326.39%
Total Cash Common Dividend	14.67%	-4.64%	-25%
Total Equity	-0.29%	-2.99%	-15.14%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Young-Jin Kim M.B.A.
Full Time Employees: 939
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 132 Teheran-ro Seoul South Korea 06235
IPO Date: Jan 4, 2000
Website: handok.co.kr
Similar Companies: Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
Aeolus Pharmaceuticals, Inc. (AOLS)
Ayr Wellness Inc. (AYR-A.CN)
Rubicon Organics Inc. (ROMJ.V)
Acusphere, Inc. (ACUS)
Cumberland Pharmaceuticals Inc. (CPIX)
Business: Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	26,830.21	27,978.22	28,607	28,894.24	31,793.4	33,567.86	32,989.58	34,450.51	36,575.84	37,548.74	39,495.99	37,956.55	- -	36,833.07
Basic EPS, GAAP	491.86	1,050.2	121	-136	-518	391	590	2,544	1,958	239	776	-2,091	- -	-3,815.94
Free Cash Flow per Basic Share	-572.25	-383.85	1,825.7	-194.74	-3,225.45	-2,727.66	580.68	-1,254.58	121.61	-451.9	-960.21	711.63	- -	-1,610.74
Dividend per Share	247.28	148.45	190.54	150.51	99.91	124.96	243.6	446.32	274.89	299.51	349.9	399.75	- -	- -
Book Value per Share	20,789.22	21,711.04	20,473.49	19,604.33	18,804.1	19,176.76	17,787.12	19,216.92	21,173.69	21,456.97	22,188.17	18,892.17	- -	17,032.65
Tangible Book Value per Share	22,708.35	23,506.36	19,666.91	18,911.86	15,335.72	15,409.75	15,833.98	18,032.18	21,052.37	21,972.16	21,726.42	18,712.2	- -	14,855.6
Basic Weighted Avg Shares	12	12	12	12	12	12	14	14	14	14	14	14	- -	14
Sales/Revenue/Turnover	314,648	327,936	348,311	358,448	396,134	417,970	446,731	473,000	503,612	517,641	543,759	522,741	507,358	507,358
Operating Margin (%)	2.73	2.28	2.96	1.74	0.92	-0.45	4.94	5.81	5.63	5.41	5.24	2.41	0.11	0.11
Depreciation Expense	11,463	11,067	13,075	14,171	14,789	17,655	19,742	21,580	21,454	21,368	21,759	22,488	23,540	23,540
Net Income, GAAP	5,768	12,310	1,473	-1,687	-6,454	4,869	7,990	34,929	26,960	3,295	10,684	-28,797	-52,563	-52,563
Effective Tax Rate (%)	41.82	20.7	59.69	- -	- -	48.43	24.42	30.01	35.96	31.03	- -	- -	- -	- -
Profit Margin (%)	1.83	3.75	0.42	-0.47	-1.63	1.16	1.79	7.38	5.35	0.64	1.96	-5.51	-10.36	-10.36
Working Capital	83,637	78,995	74,129	78,091	49,677	64,535	26,320	41,715	100,525	47,740	83,242	-6,178	-13,442	-13,442
LT Debt	20,048	20,000	54,024	61,494	89,437	105,269	50,271	93,950	154,137	139,475	185,536	124,758	144,148	144,148
Total Equity	287,252	294,276	307,774	303,706	289,250	290,711	313,376	343,995	381,849	383,996	381,856	340,633	289,060	289,060
Return on Invested Capital (%)	1.64	1.73	1.1	- -	- -	-0.2	3.47	3.69	3.04	3.02	- -	- -	- -	- -
Return on Capital (%)	2.3	4.61	0.81	- -	- -	2.18	3.18	9.14	6.2	1.35	- -	- -	- -	- -
Return on Common Equity (%)	2.39	4.94	0.58	-0.69	-2.7	2.06	3.33	13.84	9.71	1.12	3.55	-10.18	-21.25	-21.25

	Jun'24	Sep'24	Dec'24
ST Debt	160,752	210,223	229,246
LT Borrowings	168,637	149,989	142,914
LT Finance Leases	1,119	1,151	1,234
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	14	14	14
Market Capitalization	196,676	189,400	165,983

	Jun'24	Sep'24	Dec'24
Total Current Assets	300,169	324,476	327,554
Accounts Receivable, Net	141,874	146,495	138,341
Cash, Cash Equivalents & STI	17,166	28,582	56,044
Inventories	102,532	103,808	97,901
Total Current Liabilities	265,996	319,540	340,996
Payables & Accruals	- -	- -	- -
ST Debt	160,752	210,223	229,246
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	25	-113	290	- -	776
2023	-316	-442	-223	- -	-2,091
2024	-163	-936	-290	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	127,083	132,080	148,575	136,021	543,759
2023	128,373	140,552	127,230	126,587	522,741
2024	128,780	128,251	129,043	121,285	507,358

HANDOK Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year